Rosuvastatin claims
December 12, 2011
ASTRAZENECA has made patent
infringement claims against Apotex
in relation to its rosuvastatin
molecule, following Federal Court
action by the latter aimed at having
AstraZeneca’s 5 mg and 10 mg
rosuvastatin dosing patent revoked.
“It is important to note that
AstraZeneca has no patent
protection over the rosuvastatin
molecule in Australia,” a statement
from Apotex said.
“Instead, AstraZeneca is seeking
to rely on some secondary patents.
“Apotex is confident that it does
not infringe any of those patents
and that it will prevail in this
litigation,” the statement added.
In its claim, AstraZeneca is
seeking to obtain an injunction to
prevent Apotex offering for sale or
selling its rosuvastatin product.
The Federal Court hearing over
the issue is now set for 31 January
2012, however in the meantime
AstraZeneca is also seeking a short
term injunction to be heard by the
Federal Court next week.
“Challenging bad patents is an
investment Apotex is
prepared to make so that it can
bring important products to the
market, with long term benefits to
its customers and their clients,”
Apotex said.
“Apotex is continuing with its
launch plans for rosuvastatin and
anticipates PBS listing on 1 April
2012,” Apotex added.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Dec 11To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Dec 11
